BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
12/2/2015 12:16:00 PM | Browse: 322 | Download: 367
Publication Name World Journal of Hepatology
Manuscript ID 12934
Country of Manuscript Source United States
2014-07-29 08:22
Peer-Review Started
2014-07-29 19:18
To Make the First Decision
2014-08-28 14:57
Return for Revision
2014-09-01 09:58
2014-09-13 01:29
Second Decision
2014-10-10 18:07
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2014-10-10 18:26
Articles in Press
2014-10-10 18:26
Publication Fee Transferred
Edit the Manuscript by Language Editor
Typeset the Manuscript
2014-11-20 09:15
Publish the Manuscript Online
2014-11-20 19:46
ISSN 1948-5182 (online)
Open Access
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA
Website http://www.wjgnet.com
Specialty Oncology
Manuscript Type Topic Highlights
Article Title Mammalian target of rapamycin inhibition in hepatocellular carcinoma
Manuscript Source Invited Manuscript
All Author List René E Ashworth and Jennifer Wu
Funding Agency and Grant Number
Correspondence To Jennifer Wu, MD, Assistant Professor of Medicine, NYU School of Medicine, Subdivision of GI Oncology, Perlmutter Cancer Center, NYU Langone Medical Center, Division of Hematology and Oncology, 550 First Avenue, BCD 556, New York, NY 10016, United States. jennifer.wu@nyumc.org
Keywords Mammalian target of rapamycin; hepatocellular carcinoma; Mammalian target of rapamycin complex 1; Mammalian target of rapamycin complex 2; PI3K/AKT/mTOR signaling pathway; Sorafenib; Everolimus; Sirolimus; Liver transplantation; CC-223
Core Tip Advanced hepatocellular carcinoma (HCC) has a poor prognosis with limited therapeutic options. The mammalian target of rapamycin (mTOR) pathway (regulated by mTORC1 and mTORC2) is implicated in HCC pathogenesis. This review examines pre-clinical and clinical data demonstrating that mTORC1 inhibition effectively prevents HCC recurrence post-liver transplantation, and also has a modest anti-tumor effect in advanced HCC. The rationale and preclinical data for utilizing dual mTOR (mTORC1 and mTORC2) inhibition in HCC is also reviewed; a current phase?Ⅰ?clinical trial to investigate the efficacy of dual mTOR inhibitors is briefly discussed. mTOR pathway inhibition has therapeutic potential in the treatment of advanced HCC.
Publish Date 2014-11-20 19:46
Citation Ashworth RE, Wu J. Mammalian target of rapamycin inhibition in hepatocellular carcinoma. World J Hepatol 2014; 6(11): 776-782
Url http://www.wjgnet.com/1948-5182/full/v6/i11/776.htm
DOI http://dx.doi.org/10.4254/wjh.v6.i11.776
Full Article (PDF) WJH-6-776.pdf
Full Article (Word) WJH-6-776.doc
Revised Manuscript 12934-Review.doc
Peer-review Report 12934-Peer review(s).pdf
Answering Reviewers 12934-Answering reviewers.pdf
Scientific Misconduct Check 12934-CrossCheck.jpg
Scientific Editor Work List 12934-Scientific editor work list.pdf
Copyright License Agreement 12934-Copyright assignment.pdf